

# Proliferative vitreoretinopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/PA466736D544EN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PA466736D544EN

## Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Proliferative vitreoretinopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Proliferative vitreoretinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Proliferative vitreoretinopathy Understanding

#### Proliferative vitreoretinopathy: Overview

Proliferative vitreoretinopathy (PVR) is a rare ocular condition that can lead to vision loss or blindness. It occurs after retinal detachment repair surgery or as a result of an open globe injury (trauma to the eyeball). When a person develops PVR, cells in the retina start to multiply and form scar tissue. The scar tightens and pulls the retina away. There is no approved therapy for PVR, which accounts for 75% of complications following retinal detachment, and occurs in 5 to 10% of people after having retinal attachment surgery. PVR also occurs in up to 50% of people who have suffered an open globe injury.

'Proliferative vitreoretinopathy - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proliferative vitreoretinopathy pipeline landscape is provided which includes the disease overview and Proliferative vitreoretinopathy treatment guidelines. The assessment part of the report embraces, in depth Proliferative vitreoretinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proliferative vitreoretinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proliferative vitreoretinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Proliferative vitreoretinopathy.

## Proliferative vitreoretinopathy Emerging Drugs Chapters

This segment of the Proliferative vitreoretinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Proliferative vitreoretinopathy Emerging Drugs

### ADX-2191: Aldeyra Therapeutics

ADX-2191, an intravitreal formulation of methotrexate, has been granted orphan drug designation for the prevention of proliferative vitreoretinopathy (PVR). The observed clinical activity of ADX-2191 in patients with PVR is believed to be the result of down-regulation of aberrant retinal cell proliferation and activity, thereby leading to reduced retinal scarring that is characteristic of PVR. Aldeyra retains an exclusive license to certain patents related to the use of ADX-2191 for the prevention of PVR.

## PPP-003: Tetra Bio-Pharma

PPP003 (HU308) is a synthetic cannabinoid. This ophthalmic drug is currently under preclinical development and has received U.S. Food and Drug Administration Orphan Drug Designation for the prevention of proliferative vitreoretinopathy.

Further product details are provided in the report.

### Proliferative vitreoretinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Proliferative vitreoretinopathy drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Proliferative vitreoretinopathy

There are approx. 3+ key companies which are developing the therapies for Proliferative vitreoretinopathy. The companies which have their Proliferative vitreoretinopathy drug candidates in the most advanced stage, i.e. phase III include, Aldeyra Therapeutics.

#### Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

Proliferative vitreoretinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proliferative vitreoretinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proliferative vitreoretinopathy therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proliferative vitreoretinopathy drugs.

### Proliferative vitreoretinopathy Report Insights

- Proliferative vitreoretinopathy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Proliferative vitreoretinopathy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

### Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Proliferative vitreoretinopathy drugs?

How many Proliferative vitreoretinopathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proliferative vitreoretinopathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proliferative vitreoretinopathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Proliferative vitreoretinopathy and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Aldeyra Therapeutics

Tetra Bio-Pharma

Aviceda Therapeutics

## Key Products

ADX-2191

PPP-003

AVD 201

## Contents

Introduction

Executive Summary

Proliferative vitreoretinopathy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Proliferative vitreoretinopathy – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

ADX-2191: Aldeyra Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Preclinical and Discovery Stage Products

Comparative Analysis

PPP-003: Tetra Bio-Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Inactive Products

Comparative Analysis

Proliferative vitreoretinopathy Key Companies

Proliferative vitreoretinopathy Key Products

Proliferative vitreoretinopathy- Unmet Needs

Proliferative vitreoretinopathy- Market Drivers and Barriers  
Proliferative vitreoretinopathy- Future Perspectives and Conclusion  
Proliferative vitreoretinopathy Analyst Views  
Proliferative vitreoretinopathy Key Companies  
Appendix



## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Proliferative vitreoretinopathy
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Proliferative vitreoretinopathy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Proliferative vitreoretinopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PA466736D544EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PA466736D544EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970